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Abstract
Background: Impact of gender on time to initiation, response to and risk of modification of highly active
antiretroviral therapy (HAART) in HIV-1 infected individuals is still controversial.
Methods: From a nationwide cohort of Danish HIV infected individuals we identified all heterosexually infected
women (N=587) and heterosexually infected men (N=583) with no record of Hepatitis C infection diagnosed with
HIV after 1 January 1997. Among these subjects, 473 women (81%) and 435 men (75%) initiated HAART from 1
January 1997 to 31 December 2009. We used Cox regression to calculate hazard ratio (HR) for time to initiation of
HAART, Poisson regression to assess incidence rate ratios (IRR) of risk of treatment modification the first year, logistic
regression to estimate differences in the proportion with an undetectable viral load, and linear regression to detect
differences in CD4 count at year 1, 3 and 6 after start of HAART.
Results: At initiation of HAART, women were younger, predominantly of Black ethnicity and had a higher CD4
count (adjusted p=0.026) and lower viral load (adjusted p=0.0003). When repeating the analysis excluding pregnant
women no difference was seen in CD4 counts (adjusted p=0.21). We observed no delay in time to initiation of
HAART in women compared to men (HR 0.91, 95% CI 0.79-1.06). There were no gender differences in risk of
treatment modification of the original HAART regimen during the first year of therapy for either toxicity (IRR 0.97
95% CI 0.66-1.44) or other/unknown reasons (IRR 1.18 95% CI 0.76-1.82). Finally, CD4 counts and the risk of having
a detectable viral load at 1, 3 and 6 years did not differ between genders.
Conclusions: In a setting with free access to healthcare and HAART, gender does neither affect time from eligibility
to HAART, modification of therapy nor virological and immunological response to HAART. Differences observed
between genders are mainly attributable to initiation of HAART in pregnant women.
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Background
Since the introduction of highly active antiretroviral
therapy (HAART) gender differences on HIV therapies
have been reported including (i) time of HAART initi-
ation [1], (ii) adherence and toxicity to antiretroviral
drugs [2-4], and (iii) virological and immunological
response to HAART [5,6] .
Despite the reported gender differences and differ-
ences in circulating blood volume and body weight,
current treatment goals and dosage of antiretrovirals are
equivalent in HIV-1 (HIV) positive women and men [7].
One of the reasons for this may be that women are
underrepresented in many HIV clinical trials. In fact,
according to a large metaanalysis of 43 randomized clin-
ical trials from 2000–2008 women only accounted for
20% of 22,411 HIV positive subjects [8].
A reduced tolerability of antiretroviral drugs in women
compared to men has been reported [2]. Poor toler-
ability can affect adherence and an association between
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female gender and reduced rate of adherence to HAART
has been described [3,4], but findings are inconsistent and
depends on the composition of the studied cohort [4].
Most women with HIV in Europe and the US are of
childbearing age and the intention for childbearing is
high in this population [9,10]. Thus when prescribing
HAART one must consider pregnancy and avoid drugs
that are not recommended for early antenatal use e.g.
efavirenz and didanosine.
Because of the significant reduction in mortality and
rate of disease progression following HAART [11,12],
surrogate markers of disease progression such as viral
load and CD4 count have been introduced [13,14].
Most studies report no gender-related differences in
terms of virological and immunological response to
HAART, however data are conflicting [2,6,8,15].
In the present study we used a nationwide, population
based cohort of heterosexually infected individuals to es-
timate gender differences in initiation of HAART
regarding timing, regimen and modifications. Moreover,
we aimed to estimate the effectiveness of HAART by
means of viral load and CD4 count in genders in a
setting with free access to HAART and healthcare.
Methods
Setting
Denmark has a population size of 5.6 million [16] and
an estimated HIV prevalence among adults of 0.1%
[17]. Medical care, including HAART, is tax-paid and
provided free-of-charge to all HIV-infected residents
in Denmark. Treatment of HIV-infected patients is
restricted to eight specialized medical centres, where
patients are seen on an outpatient basis at intended
intervals of 12–24 weeks. National criteria for initiation
of HAART are: (i) acute HIV-infection, (ii) HIV-related
disease or an AIDS defining illness (ADI), (iii) preg-
nancy, (iv) until 1 May 2008 a CD4 count below
300 cells/μl and hereafter a CD4 count below 350 cells/μl
and (v) until 31 December 2001 HIV-1 RNA > 100,000
copies/mL [18].
The Civil Registration System (CRS)
The CRS is a national registry of all Danish residents
containing information on date of birth, sex, address,
date of migration and date of death. At birth or immi-
gration a 10-digit personal number is assigned to each
individual (CPR), which enables treatment centres to
avoid multiple registrations of the same patient. We
used the CPR to link data from the CRS to the Danish
HIV Cohort Study.
Danish HIV Cohort Study (DHCS)
The DHCS is a prospective, observational, nationwide,
multicentre population-based cohort study of all HIV-
infected patients seen at the Danish HIV clinics since 1
January 1995. The cohort has been described in details
elsewhere [19]. In brief, the data collection is ongoing,
with continuous enrolment of both newly diagnosed
residents and immigrants with HIV. The database is
updated annually and among other variables it contains
data on: date of birth, gender, route of transmission,
race, date of first HIV-1 positive test, bodyweight, immi-
gration and emigration, date of death, date of HAART
initiation, HAART regimens and reasons for modifica-
tions. Laboratory data include cumulative CD4 counts
and HIV RNA among others. Status of pregnancy was
extracted from the Danish National Hospital Database.
Ethics
The study has been approved by the Danish Data
Protection Agency (jr. 2001-41-0624).
The DHCS is approved by the Danish Data Protection
Agency. Since data collection did not involve direct
patient contact the study was not subject to approval by
the Danish Research Ethics Committee.
Study population
We describe two cohorts in this study: Cohort 1: Hetero-
sexually infected adult women and men diagnosed with
HIV in Denmark from 1 January 1997 to 31 December 2009
with no record of Hepatitis C (HCV) infection. Cohort 2:
Patients in the above mentioned cohort initiating
HAART from 1 January 1997 to 31 December 2009.
Definitions
HAART was defined as the combination of antiretroviral
treatment with at least three drugs, including at least one
non-nucleoside reverse-transcriptase inhibitor (NNRTI)
or a protease inhibitor (PI), and/or abacavir, or a treatment
regimen with a combination of a NNRTI and a boosted PI
[18]. We categorized treatment modifications into 3
groups: virological failure, toxicity (covering: abnormalities
of body fat distribution, dyslipidaemia, hypersensitivity,
gastrointestinal toxicity, neurological toxicity, nephro-
logical toxicity, endocrinological toxicity and other tox-
icity) and other/unknown (covering: patient’s wish,
doctor’s decision, other cause, unknown, as part of modi-
fication to another HAART, problems with adherence).
Data were based on medical files.
Virological failure was defined as such if the physician
treating the patients’ HIV infection had stated virological
failure as the reason for modification in the medical file.
Undetectable viral load was defined as a plasma HIV
RNA load of <500 copies/mL, which was the highest
level of sensitivity for testing in the observation period.
We defined acute HIV infection as clinical seroconver-
sion with a positive Western blot pattern.
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CD4 count and HIV RNA at HAART initiation were
defined as the latest value measured before initiation of
therapy. Hepatitis B (HBV) co-infection was defined as
being hepatitis B surface antigen (HbsAg) positive.
Statistical analyses
Start of the observation period for cohort 1 was defined
as date of eligibility for therapy as described above and
patients were followed to initiation of HAART, emigra-
tion, death or 31 December 2009, whichever came first.
Cohort 1 is used in the analysis of time from eligibility
for therapy to HAART initiation.
In cohort 2 patients were observed from date of
HAART initiation and censored at emigration, death
or 31 December 2009, whichever came first. Cohort 2
was studied in all analyses, but timing of HAART
initiation.
A patient was considered eligible for therapy the
day they fulfilled one of the above mentioned national
criteria concerning CD4 count, HIV RNA or AIDS.
The incentive for initiation of HAART during preg-
nancy, acute HIV infection and in HBV coinfection is
different than in patients starting HAART due to an
impaired immune system, i.e. low CD4 count. In the
analysis of time from eligibility to HAART initiation we
therefore excluded patients initiating HAART before
they were eligible for therapy.
Information on initiation of HAART due to non-AIDS
defining HIV related disease was not available in the
DHCS and therefore not assessed in the analysis of
being eligible for start of HAART. When studying the
actual number of patients initiating HAART during
acute HIV infection this was defined as a patient with
acute HIV infection initiating therapy during the first
3 months after HIV diagnosis.
Intergroup characteristics were compared using Wilcoxon
rank sum test for continuous variables and chi-square
test and Fisher’s exact test for categorical variables.
Median and interquartile ranges (IQR) were determined
for continuous variables. The CD4 count at initiation of
HAART was subsequently log-transformed and analysed
in linear regression adjusting for age, ethnicity and
period of initiation. AIDS was not included in this ana-
lysis as covariate, since the CD4 count and AIDS are
dependent covariates. Likewise, viral load at initiation
of HAART was log-transformed and analysed in linear
regression adjusting for age, ethnicity, period of initiation
and prior or current AIDS at start of HAART.
To assess linearity, continuous variables were entered
in the model as second degree polynomials and reduced
as appropriate. Significance level was set at 0.05 (two-
sided).
To evaluate the response to HAART, the CD4 and
HIV RNA values were grouped in 12-week intervals and
computed as described elsewhere [20]. The absolute
CD4 counts were log-transformed and analysed in linear
regression and adjusted as mentioned above at 1 year
(48 weeks), 3 years (156 weeks) and 6 years (312 weeks).
Furthermore, we estimated the proportion of patients
achieving an undetectable viral load during follow-up.
Logistic regression model was used to compare preva-
lence of detectable viral load between genders at year 1,
3 and 6. Odds ratios (OR’s) and correlating 95% confi-
dence intervals (CI) were estimated and adjusted for
age, ethnicity, period of initiation and prior or current
AIDS at initiation of HAART. The validity of the model
was tested using the Hosmer and Lemeshow Goodness-
of-Fit Test.
The cumulative incidence function with death as a
competing risk were computed for time from eligibility
of therapy to HAART initiation. To estimate the hazard
ratio (HR) and associated 95% CI, we used Cox propor-
tional hazards models and adjusted for race and time-
updated age (18–29, 30–39, 40–49, 50–59, 60–69 and
70–100 years). Due to non-proportionality of period of
initiation the analysis was stratified for period of initi-
ation of HAART.
In the sensitivity analyses women initiating HAART
due to pregnancy, women were excluded if date of
HAART initiation was within the period of one year
before the conception (estimated as 37 weeks before
delivery) or during pregnancy.
Two periods: 1997–2002 (the early HAART period)
and 2003–2009 (the late HAART period) and five initial
HAART regimens were assessed for analysis in this
study: i) 3 nucleoside reverse transcriptase inhibitors
(NRTI’s), ii) 2 NRTI’s + efavirenz, iii) 2 NRTI’s + nevira-
pine, iv) 2 NRTI’s + PI/ritonavir or PI and v) other
HAART regimen.
Poisson regression analyses were used to estimate IR,
IRR and corresponding 95% CI of the first modification
of treatment due to toxicity and other/unknown the first
year after initiation of HAART and were adjusted by
time-updated age (18–29, 30–39, 40–49, 50–59, 60–69,
70–100 years), race, time-updated CD4 count (<200,
200–350 and >350 cells/μl), time-updated viral load
(< 50,000, 50,000-100,000 and > 100,000 copies/mL),
prior or current AIDS at HAART initiation, body weight
(<50, 50–70, 71–100 and >100 kg), initiation period < 1
January 2003 and >= 1 January 2003. Modification due to
failure could not be assessed because of small numbers.
A composite table was computed with reasons for
switching due to toxicity. In these analyses a patient
could only contribute with one modification of each rea-
son. In each category with more than five changes of
regimen IR’s and corresponding 95%CI and IRR’s and
corresponding 95%CI adjusted for the same confounders
as mentioned above in the analyses of IRR.
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The cumulative incidence function of time from eligi-
bility to HAART initiation were done using R-2.12.2
[21] and the cmprsk library by Bob Gray.
SAS statistical software version 9.2 (SAS Institute Inc.,
Cary, NC, USA) was used for data analysis.
Results
Time from eligibility to HAART initiation
A total of 1170 heterosexually infected women and men
reached eligibility for HAART. Subsequently, HAART
was initiated in 473 (52.1%) women and in 435 (47.9%)
2660 Diagnosed before Jan 1, 1997.
Age < 18 years at diagnosis.
HIV-2-infected, tourist, or living in Greenland.
Intravenous drug users.
No route of infection or sex registered.
Other route of infection than sexually transmission.
HIV diagnosis before immigration.
Hepatitis C co-infection.
65
103
196
33
157
82
119
262
1089
908
5674
1170 Cohort 1
Cohort 2
Infected homosexually.
Did not initiate HAART in the study period.
473 435
HIV infected patients in the Danish HIV Cohort Study.
Figure 1 Flowchart of HIV infected patients in the Danish HIV Cohort Study.
Figure 2 The cumulative incidence function with death as a competing risk for time from eligibility of therapy to HAART initiation
stratified by gender.
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Table 1 Patient characteristics at initiation of HAART stratified by gender (n = 908)
Women Men p-value1
Subjects, n(%) 473 (52.1) 435 (47.9) -
Follow-up from initiation of HAART (years), median (IQR) 5.9 (3.2-8.7) 5.7 (2.7-8.5) -
Follow-up time from initiation of HAART, (person-years) 2833 2519
Age in years at HAART initiation, median (IQR) 33.0 (28.6-40.1) 43.2 (35.3-51.7) <0.0001
Race, n(%)
White 137 (29.0) 319 (73.7) <0.0001
Asian 76 (16.1) 12 (2.8)
Black 250 (53.0) 90 (20.8)
Other 9 (1.9) 12 (2.8)
(missing) (1) (2)
Place of HIV transmission, n(%)
Denmark 127 (28.5) 150 (38.3) <0.0001
Europe + US 19 (4.3) 29 (7.4)
Africa 224 (50.3) 140 (35.7)
Asia 72 (16.2) 63 (16.1)
Other 3 (0.7) 10 (2.6)
(missing) (28) (43)
CD4 cell count at HAART initiation (cells/μl), median (IQR)
All women included 196 (90–290) 180 (63–290) 0.12 (0.026)
Pregnant women excluded 170 (80–270) 180 (63–290) 0,87 (0,21)
HIV-RNA at HAART initiation (copies/mL), median (IQR)
All women included
50,800 (12,500-204,000) 126,155 (32,200-501,000) <0.0001 (0.0003)
Pregnant women excluded 61,320 (16,519-237,000) 126,155 (32,200-501,000) <0.0001 (0.0066)
Acute HIV infection at HAART initiation, n(%) 4 (0.9) 15 (3.5) 0.0089
AIDS before HAART initiation, n(%) All women included 88 (18.6) 106 (24.4) 0.034
n(%) of all patients except pregnant women Pregnant
women excluded
87 (21.8) 106 (24.4) 0.37
Pregnant at HAART initiation, n(%) 59 (12.5) - -
Antiretroviral therapy before HAART, n(%) 14 (3.0) 12 (2.8) 0.86
Hepatitis B co-infection2, n(%) 30 (6.3) 20 (4.6) 0.25
Hepatitis C co-infection3, n(%) 0 (0) - -
First-line HAART 01.01.1997 – 31.12.2002 All women included
3 NRTI’s4 21 (9.5) 9 (4.3) 0.29
2 NRTI’s + efavirenz 71 (32.0) 76 (35.9)
2 NRTI’s + nevirapine 7 (3.2) 6 (2.8)
2 NRTI’s + PI’s5 93 (41.9) 94 (44.3)
Other regimen 30 (13.5) 27 (12.7)
Pregnant women excluded
3 NRTI’s 21 (11.1) 9 (4.7) 0.13
2 NRTI’s + efavirenz 66 (37.7) 76 (39.8)
2 NRTI’s + nevirapine 5 (2.6) 6 (3.1)
2 NRTI’s + PI’s 73 (38.4) 94 (44.3)
Other regimen 25 (13.2) 27 (12.7)
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men during follow-up (Figure 1). Figure 2 presents
curves for time from eligibility to initiation of HAART
stratified by gender. We found no difference in time to
initiation of HAART between genders (HR 0.91 95% CI,
0.79-1.06, unadjusted p=0.98, adjusted p=0.21 (women
vs. men).
Patient characteristics
Clinical and demographic characteristics at initiation of
HAART are presented in Table 1. Total follow-up: 5352
person-years. Women were younger, a greater propor-
tion of women were of Black and Asian ethnicity
(p<0.0001) and had acquired HIV abroad (p<0.0001).
Women initiated HAART at higher CD4 counts
(adjusted p=0.026) and lower viral loads (adjusted
p=0.0003). Fifty-nine women (12.5%) initiated HAART
due to pregnancy. When repeating the analysis excluding
women who initiated HAART due to pregnancy there
was no difference in median CD4 counts at initiation of
HAART (adjusted p=0.21). Prior or current AIDS and
acute HIV infection at HAART initiation were more fre-
quent in men. During the late HAART era women were
more likely to receive a HAART regimen comprising 2
NRTI’s + either PI/r or unboosted PI (29.1% vs. 9.0%),
and less likely to initiate a 2 NRTI’s + efavirenz based
regimen (59.8% vs. 80.3%) than men (p<0.0001). This
difference was not significant when women initiating
HAART due to pregnancy were excluded.
Modification of HAART
During the first year after initiation of HAART, gender
had no impact on risk of first modification of treatment
due to either toxicity (adjusted incidence rate ratio
women vs. men, IRR, 0.97 95% confidence interval (CI)
0.66-1.44) or other/unknown reasons (adjusted IRR
women vs. men 1.18 95% CI, 0.76-1.85) (Table 2). Nor
did the estimates change when we excluded bodyweight
(data not shown). Only 5 (1.3%) women and 4 (1.5%)
men switched HAART regimen because of virological
failure and therefore this aspect was not further explored.
Overall, the four most common reasons for change of
HAART were hypersensitivity, gastrointestinal toxicity,
neurological toxicity and other toxicity (Figure 3).
Women were more likely to modify their treatment due
to gastrointestinal toxicity (9.1% vs. 4.6%, p=0.0078).
However, the adjusted IRR of risk of switching did not
exhibit gender differences (Table 3).
Response to HAART
We estimated the proportion of patients with an
undetectable viral load after initiation of HAART (Figure 4).
One year after initiation of HAART 83% of women
and 92% of men had gained viral control (viral load <
500 copies/ml), adjusted OR 1.24 (95%CI 0.72-2.14).
After 3 and 6 years the proportion of women and men
with an undetectable viral load was 82% and 87%,
respectively, adjusted OR 0.92 (95%CI 0.53-1.61), and
83% and 87%, respectively, adjusted OR 0.87 (95%CI
0.41-1.84)
We found no statistically significant differences in
median CD4 count between genders after initiation of
HAART. At year 1 the median CD4 count was 330 cells/
μl IQR(210–457) in women and 360 cells/μl IQR(220–
510) in men (adjusted p=0.90) at 3 years 459 cells/μl
IQR(316–600) in women and 469 cells/μl IQR(318–656)
in men (adjusted p=0.90) and at 6 years 530 cells/μl IQR
(380–696) in women and 582 cells/μl IQR(382–793) in
men, (adjusted p=0.90) (Figure 5).
Table 1 Patient characteristics at initiation of HAART stratified by gender (n = 908) (Continued)
First-line HAART 01.01.2003 – 31.12.2009 All women included
3 NRTI’s 3 (1.2) 1 (0.5) <0.0001
2 NRTI’s + efavirenz 150 (59.8) 179 (80.3)
2 NRTI’s + nevirapine 17 (6.8) 13 (5.8)
2 NRTI’s + PI’s 73 (29.1) 20 (9.0)
Other regimen 8 (3.2) 10 (4.5)
Pregnant women excluded
3 NRTI’s 3 (1.4) 1 (0.5) 0.066
2 NRTI’s + efavirenz 148 (70.5) 179 (80.3)
2 NRTI’s + nevirapine 15 (7.1) 13 (5.8)
2 NRTI’s + PI’s 36 (17.1) 20 (9.0)
Other regimen 8 (3.8) 10 (4.5)
Figures are number (%) or median (interquartile range - IQR).
1 P-values were calculated using chi-square or Fisher’s exact test (when appropriate) for categorical variables and Kruskal-Wallis test for continuous variables. CD4
cell counts and viral loads were subsequently analysed by linear regression adjusting for age and race (p-value in parenthesis). 2 Patients with positive Hbs-Ag in
the study period, 3 Hepatitis C was an exclusion criteria, 4 Nucleoside reverse transcriptase inhibitors (NRTI), 5 Protease Inhibitors (PI’s).
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Discussion
Trial data on HIV therapies in women are limited [8]
and discrepant results regarding the impact of gender on
HAART have been reported [2]. Here, we found that in
a setting with free access to healthcare and HAART gen-
der did neither affect time from eligibility to HAART,
modification of therapy nor virological and immuno-
logical response to HAART.
In line with our study, European cohorts report no
gender differences in time from eligibility to initiation of
therapy [22,23], while in the US a propensity to delay
HAART in women compared to men is seen [24-26].
Though, studies defined eligibility differently the estimated
differences could be attributed to the reported inequality
in access to HAART and healthcare in the US more than
gender itself [27]. In Europe, overall there is equality in
access to HAART between genders, though in central and
eastern Europe women tends to be favored over men [28].
The enormous benefit of HAART is reflected by few
clinical outcomes [12,29] and therefore we assessed clin-
ical progression by means of the virological and im-
munological response in patients seen after initiation of
HAART. Additionally, we have earlier reported that in
Denmark no major differences in terms of progression
to AIDS and death are seen between men who have sex
with men (MSM), heterosexually infected men and het-
erosexually infected women [30]. Therefore we decided
to focus on HIV positive patients infected heterosexually
to study patients living in the same social context [6].
We excluded intravenous drug users and HCV coin-
fected patients, since studies repeatedly report worse
clinical outcomes [31-33] and weaker immunological
and virological responses in these patients [22,34]. Fur-
thermore, due to concerns about residual confounding
when adjusting for IDU in the model, we chose to per-
form restricted analyses with exclusion of this group
of patients.
Data on gender differences in CD4 count recovery
after initiation of HAART are discrepant. In agreement
with others [6,14,15,22] we found no differences in CD4
recovery. On the contrary several studies report a bene-
ficial immunological outcome in women [5,35-37].
The lower viral load seen in women at initiation of
therapy even when we excluded pregnant women is sup-
ported by several studies [2,3,15,22,35,38,39] and prob-
ably has no influence on disease progression [2].
Compared to other cohorts [5] where HIV RNA was un-
detectable in 48-79% of all patients a relatively high pro-
portion of our patients (83% of women and 92% of men)
had undetectable viral load after 1 year, though, different
definitions of viral suppression make studies difficult
to compare.
We found no difference in virological response during
follow-up between men and women, which is in accord-
ance with earlier reports on gender differences [1,15,22],
however during the entire follow-up the proportion of
men who had gained full viral control was greater than
that of women.
Table 2 Incidence rates, IR (per 1 person-year), incidence rates ratios, IRR, of reasons of treatment modifications the
first year after initiation of HAART according to gender
Toxicity
IR (95% CI)
Other/Unknown
IR (95% CI)
Toxicity
IRR (95% CI)
Other/Unknown
IRR (95% CI)
Adjusted for all listed confounders,
Men 0.52 (0.42-0.64) 0.55 (0.44-0.68) 1.00 1.00
Women 0.49 (0.41-0.59) 0.57 (0.48-0.67) 0.97 (0.66-1.44) 1.18 (0.76-1.85)
Women (pregnant excluded) 0.54 (0.45-0.66) 0.49 (0.40-0.61) 1.03 (0.69-1.52) 1.14 (0.71-1.82)
Poisson regression analyses of incidence rates, IR (95% CI), and incidence rates ratios, IRR (95% CI), adjusted by time-updated age, race, time-updated CD4 count,
time-updated viral load, prior or current AIDS at HAART initiation, body weight and initiation period (< January 1st 2003 and >= January 1st 2003).
Table 3 Incidence rates, IR (per 1 person-year), incidence rates ratios, IRR, of risk of treatment modification due to
different types of toxicities
Incidence rates and incidence rate ratios
for changes in HAART during the first
year due to the following reasons:
Women
IR 95%(CI)
Men
IR 95%(CI)
Women vs. men (ref)
unadjusted IRR 95%(CI)
Women vs. men (ref)
adjusted IRR 95%(CI)
Toxicity, hypersensitivity 0.09 (0.06-0.15) 0.06 (0.03-0.14) 1.43 (0.58-3.52) −1
Toxicity, gastrointestinal 0.22 (0.16-0.15) 0.16 (0.10-0.26) 1.37 (0.80-2.36) 0.97 (0.49-1.93)
Toxicity, neurological 0.19 (0.13-0.27) 0.20 (0.13-0.30) 0.96 (0.56-1.64) 1.48 (0.65-3.38)
Toxicity, other 0.18 (0.13-0.25) 0.29 (0.21-0.40) 0.62 (0.39-1.00) −1
1 No estimate available, due to shortage of events.
Poisson regression analyses of incidence rates, IR (95% CI), and incidence rates ratios, IRR (95% CI), adjusted by time-updated age, race, time-updated CD4 count,
time-updated viral load, prior or current AIDS at HAART initiation, body weight and initiation period (< January 1st 2003 and >= January 1st 2003).
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Only a small part of patients were ART experienced
before HAART initiation and this proportion did not
differ between genders. Along with others [5], we found
that women were less likely to receive a HAART regi-
men containing efavirenz. Since the publication of
teratogenicity in animal studies [40] and of neural tube
defects in infants exposed to efavirenz in their first tri-
mester [41] guidelines have recommended avoiding this
drug in women likely to conceive. Indeed, after exclud-
ing women who initiated HAART due to pregnancy
from our analysis the initial HAART regimen did not
differ significantly between genders.
Regarding pharmacokinetics on HAART, data are lim-
ited, but current evidence suggests that gender differ-
ences exist [42]. Reportedly, women have been found to
be more likely to discontinue ART due to neurological
[39] and dermatologic symptoms [3,23,43]. Furthermore,
an increased risk of lactic acidosis [44], HIV lipodystro-
phy [23,45] and hepatic dysfunction [46] have been
reported in women. Some have speculated that the
higher rate of adverse effects in women are caused by a
higher drug exposure in women [35].
Our multivariate model failed to show more treatment
modifications in women of the original HAART regimen
0 10 20 30 40 50
Other toxicity
Endocrinological toxicity
Nephrological toxicity
Neurological toxicity
Gastrointestinal toxicity
Hypersensitivity
Dyslipidaemia
Abnormal body fat distribution
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Figure 3 Number of patients reporting modification of HAART during the first year after initiation due to toxicity for the
reasons listed.
Figure 4 Proportion of patients with an undetectable viral load during the study period.
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the first year after initiation compared to men. This find-
ing is supported by others [3,6,8]. Because dosing regi-
mens of HAART are not gender specific, we adjusted for
bodyweight in the analysis of IRR for treatment modifi-
cations and this did not alter results. Nor exclusion of
pregnant women changed results significantly.
In contrast to our study four studies [23,37,47,48]
found that women were more likely to discontinue treat-
ment than men. However, the first two studies have not
considered pregnancy and in the latter two women were
excluded when becoming pregnant. However, the UK
CHIC study was able to take pregnancy into account and
in this cohort women were more likely to discontinuate
treatment for reasons other than virological failure [5].
We found that women were more likely to change
regimen due to gastrointestinal toxicity, though, this
information needs to be interpreted with care due to
small numbers.
As earlier stated some studies report that women are
more likely to change regimen, because of HIV lipody-
strophy [23,45]. Since we focus on the first year after ini-
tiation of HAART only, we probably do not allow for
sufficient time for this to be of clinical significance [49].
The major strength of our study is the nationwide
population-based design, linking the nationwide registers
DHCS and CRS with minor loss to follow-up [50] and
access to electronically collected longitudinal data on
HIV RNA and CD4 counts.
Some limitations need to be assessed. Data on adher-
ence and socioeconomic status are not available in
our cohort and are therefore not assessed for analysis.
Information on the study participants was those reported
by the providers and then retrospectively summarized
for this study. In the DHCS only toxicities leading to a
modification are documented and therefore the risk
of adverse events might be substantially higher than the
incidence reported in our study. Moreover, data on
virological failure is based on the discretion of the phys-
ician and might therefore not reflect the actual number
of virological failures.
The route of transmission is self-reported and there-
fore can be misclassified. Furthermore, infection with
HCV and HBV was not treated as a time-updated vari-
able, as this information is not available in DHCS.
Conclusions
In a setting with free access to healthcare and antiretro-
viral drugs gender has no impact on time to initiation
of HAART, modification of therapy the first year or
response to HAART. The differences observed between
genders are mainly attributable to initiation of HAART
in pregnant women.
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